Skip to content 
Before walking into a regenerative medicine consultation, many patients have already done hours of research.
They have Googled their diagnosis.
Watched videos.
Read Reddit threads.
Asked ChatGPT or another AI tool.
Found clinical trials.
Compared clinics.
Read patient testimonials.
And probably encountered two completely opposite conclusions:
“Stem cells can fix almost anything.”
and
“Stem cell therapy is completely fake.”
Neither extreme is particularly helpful.
Regenerative medicine is an active area of research involving many different cell sources, products, doses, routes of administration, diseases, and stages of clinical evidence.
That means the most useful skill is not finding someone online who agrees with what you hope is true.
It is learning how to evaluate the information you find.
At The Re/ Clinic in Sandy, Utah, we encourage patients to research their options and bring questions to their consultation.
Here is how to do that more effectively.
Table of Contents
Quick Answer: How Should You Research Stem Cell Therapy?
When you find a claim about stem cell therapy online, ask:
- What exact cell or tissue product was studied?
- Was the research performed in humans?
- Was it a randomized controlled trial, an observational study, a case report, or something else?
- What outcome actually improved?
- Does the study involve the same diagnosis you have?
- Have other high-quality studies found similar results?
- What is the current FDA status of the product and indication?
- How does it compare with established treatment alternatives?
Those questions matter because a study involving one stem-cell product cannot automatically prove that a completely different stem-cell product works.
Likewise:
A mouse study is not a human clinical trial.
A registered clinical trial is not an FDA approval.
A statistically significant change is not automatically a meaningful improvement for a patient.
And:
One promising study does not settle an entire scientific question.
Watch: Dr. John Dame and Dr. Rob Kellar Discuss Today’s Informed Patient
Video Transcript
Dr. Rob Kellar:
How often are patients fact-checking you when you’re with them, like with AI?
Dr. John Dame:
I would say it’s almost every patient at this point.
And it’s not necessarily like a challenge as much as it is, you’ve said this, and I’ll give them advice regarding a stem-cell treatment or advice in certain areas, and then they’ll go, “When I was looking into that, this is what I found.”
Then I need to be able to respond and interact with them on that information they’ve gathered.
They’re no longer just, “Oh doc, you tell me what the right thing is and I’ll do that.”
It’s so much more of, “I’m informed because of experience,” and there’s lots of social media as well as internet resources that help patients become educated.
Then they come with very educated questions, very educated ideas about what they’re looking for.
It’s a great feed for us in the sense of they know that they want what we have because they’ve seen that it works and helps.
Then for me, it’s just saying, “This is how it applies to you.”
We see these patients that come in with really bad degenerative arthritis.
They want to know, “Gosh, my orthopedist is saying surgery’s the only thing to fix this.”
And that’s not necessarily entirely true because surgery has its own host of complications.
Dr. Rob Kellar:
Of course.
Dr. John Dame:
And so if we can get them clinically feeling better, sometimes it’s even just for a matter of months to years, that’s adequate to be beneficial to them.
Important Context About the Video
We agree with the central message:
Patients asking informed questions is a good thing.
But several statements in a short conversation like this deserve additional context.
“They’ve seen that it works and helps.”
Online testimonials, social-media videos, clinic experiences, and patient stories can help someone understand what treatment is like.
They cannot establish how effective a medical treatment is.
Clinical effectiveness is better evaluated through controlled human research that measures outcomes across groups of patients.
And even controlled trials can disagree.
For example, a 2023 randomized phase III trial involving an allogeneic bone-marrow-derived MSC product for knee osteoarthritis reported better pain and functional outcomes than placebo. (PubMed)
But a larger 2025 phase IIb randomized trial involving a different, autologous adipose-derived MSC product found no significant improvement in pain or function compared with saline placebo. (PubMed)
Both are stem-cell studies.
They do not have the same result.
That is exactly why:
“I found a study showing stem cells work”
is only the beginning of the conversation.
“My orthopedist says surgery is the only thing to fix this.”
For some patients with advanced degenerative joint disease, surgery is an established and evidence-supported treatment.
A randomized trial of patients with moderate-to-severe knee osteoarthritis who were eligible for total knee replacement found greater improvement in pain and function with knee replacement plus nonsurgical care than with nonsurgical care alone, although surgery was also associated with more serious adverse events. (PubMed)
AAOS maintains evidence-based guidelines specifically for the surgical management of symptomatic knee osteoarthritis. (American Academy of Orthopaedic Surgeons)
That does not mean every patient with arthritis needs immediate surgery.
It means the fairest discussion should include:
- What surgery is expected to accomplish
- Its risks
- Nonsurgical alternatives
- The evidence for those alternatives
- The patient’s goals
- Whether delaying surgery is reasonable
Regenerative medicine should not be positioned as proving an orthopedic surgeon wrong.
It should be considered within the full set of options available to an individual patient.
“Months to years of benefit.”
Some studies of particular biologic products have reported improvements lasting months or longer.
But a specific duration of benefit cannot be guaranteed for an individual patient or generalized across different products.
That is an outcome to discuss, not promise.
1. Why Stem Cell Research Is So Easy to Misinterpret
The phrase:
“stem cell therapy”
sounds like one treatment.
It is not.
A research paper might involve:
- Bone-marrow-derived MSCs
- Adipose-derived MSCs
- Umbilical-cord-derived MSCs
- Hematopoietic stem cells
- Culture-expanded cells
- Minimally processed tissue
- Autologous cells
- Allogeneic donor cells
The cells might be:
- Fresh
- Cryopreserved
- Expanded
- Low passage
- High passage
- Genetically modified
- Combined with another treatment
And they might be administered:
- Into a joint
- Intravenously
- During surgery
- Into another tissue
The study might involve:
- Knee osteoarthritis
- Graft-versus-host disease
- Spinal cord injury
- Heart disease
- A tendon
- Another entirely different condition
So the statement:
“A study proved stem cells work.”
is scientifically incomplete.
A better question is:
Which cells, prepared how, given at what dose, by which route, to which patients, for what condition, compared with what control, and measuring what outcome?
2. Question 1: What Exact Product Was Studied?
This may be the single most important question.
Imagine you find a clinical trial reporting promising results from:
25 million culture-expanded allogeneic bone-marrow-derived MSCs.
The clinic you are considering uses:
an umbilical-cord-derived product.
Those are not automatically interchangeable.
Cell source can affect:
- Growth characteristics
- Secreted signaling molecules
- Immune characteristics
- Culture behavior
- Manufacturing
- Final product composition
The same problem occurs when patients read research involving autologous bone marrow and assume it proves something about donor umbilical-cord tissue.
Or vice versa.
When reading a study, look for:
Source
Where did the cells come from?
Autologous vs Allogeneic
Did they come from the patient or a donor?
Processing
Were they isolated or culture-expanded?
Passage
How much expansion occurred?
Dose
How many cells were administered?
Route
Was treatment local or systemic?
Other Treatments
Was the biologic given alone or alongside:
- Surgery?
- Hyaluronic acid?
- PRP?
- Rehabilitation?
- Another treatment?
That final point can completely change the interpretation.
If a study tests a biologic during surgical meniscus repair, it does not automatically prove that injecting the biologic instead of performing repair will produce the same result.
3. Question 2: Was the Research Actually Done in Humans?
There are several stages of medical research.
Laboratory Research
Researchers may expose cells to a substance in a dish.
This can help answer biological questions.
It cannot tell you whether a treatment will improve symptoms in a human patient.
Animal Research
A treatment might improve cartilage in a rat or tendon structure in a rabbit.
That can justify further study.
Humans are not large rats.
Many treatments that look promising in animal models fail to demonstrate the same clinical effect in people.
Human Research
Human studies move us closer to the question patients actually care about:
Will this help someone like me?
But even among human studies, evidence quality varies enormously.
4. Question 3: What Kind of Human Study Was It?
Not every human study provides the same level of evidence.
Case Report
A physician describes what happened to one patient.
Useful for identifying interesting observations.
Very weak evidence for determining effectiveness.
Case Series
Several patients receive treatment and their outcomes are described.
Better than one patient.
Still no true control group.
Observational Study
Researchers observe outcomes without randomly assigning treatments.
Useful, but differences between groups can affect results.
Randomized Controlled Trial
Patients are randomly assigned to different groups.
Ideally one receives the treatment and another receives:
- Placebo
- Standard care
- Another active treatment
Randomization helps reduce bias.
Blinded Trial
Patients, researchers, or both may not know which treatment was administered.
This matters particularly for outcomes such as pain, where expectations can influence reported results.
When someone says:
“There’s a clinical study showing this works,”
ask what kind.
5. Question 4: What Did the Study Actually Measure?
Study headlines can be misleading if you do not look at the primary outcome.
A trial may measure:
- Pain score
- Physical function
- Cartilage thickness
- MRI signal
- Blood biomarkers
- Range of motion
- Quality of life
- Need for surgery
Those outcomes are not equivalent.
For example:
A change in an inflammatory biomarker does not automatically mean the patient felt better.
Likewise:
Pain improving does not necessarily prove cartilage regrew.
And:
An MRI change does not necessarily mean the patient experienced meaningful functional improvement.
A particularly useful question is:
Was the difference clinically meaningful, or only statistically significant?
A tiny difference can be statistically significant in a large enough trial without being large enough for the average patient to notice.
6. Question 5: Does the Study Match Your Diagnosis?
This seems obvious.
It gets ignored constantly.
Research involving knee osteoarthritis does not automatically prove effectiveness for:
- ACL tears
- Meniscus tears
- Rotator cuff tears
- Back pain
- Achilles tendinopathy
Likewise, a study of mild-to-moderate arthritis does not necessarily tell us what will happen in someone with a severely deformed, end-stage joint.
Look at the study’s inclusion criteria.
Ask:
- What ages were enrolled?
- What disease severity?
- Acute or chronic injury?
- Previous surgery?
- Mild, moderate, or severe degeneration?
- What exclusions were used?
Then ask:
How similar were those patients to me?
7. Question 6: Has the Result Been Reproduced?
This is where reading more than one paper becomes incredibly important.
Consider knee osteoarthritis.
One randomized phase III study of a specific allogeneic bone-marrow-derived MSC product reported clinically favorable results. (PubMed)
A small randomized placebo-controlled bone-marrow MSC trial published more recently also reported improvements in some patient-reported outcomes. (PubMed)
But the 2025 ADIPOA2 randomized phase IIb trial of adipose-derived MSCs did not find significantly better pain or function than placebo. (PubMed)
Those findings do not mean:
“Stem cells work.”
or:
“Stem cells don’t work.”
They mean:
Different products, trials, doses, populations, and methods can produce different results.
That uncertainty is part of the evidence.
Do not hide from it.
8. Question 7: What Is the FDA Status?
This is one of the easiest claims to fact-check and one of the most frequently misunderstood.
In December 2024, FDA approved Ryoncil, or remestemcel-L-rknd, an allogeneic bone-marrow-derived mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older. It became the first FDA-approved MSC therapy in the United States. (U.S. Food and Drug Administration)
That is important.
But FDA approval is product specific and indication specific.
Ryoncil’s approval does not mean mesenchymal stromal cells as an entire category are FDA-approved for:
- Knee arthritis
- Shoulder pain
- Rotator cuff tears
- Back pain
- Tendon injuries
- Anti-aging
- Chronic fatigue
- General wellness
FDA continues to state that regenerative medicine products have not been approved for orthopedic conditions such as osteoarthritis, tendonitis, disc disease, knee pain, back pain, hip pain, neck pain, and shoulder pain. (U.S. Food and Drug Administration)
So when researching a clinic, do not ask only:
“Are stem cells FDA-approved?”
Ask:
“Is this exact product FDA-approved for this exact condition?”
Those are different questions.
9. FDA-Registered Does Not Mean FDA-Approved
This one deserves its own section because the terms sound similar.
A company, laboratory, tissue establishment, pharmacy, or facility may be:
FDA-registered.
That does not automatically mean FDA has evaluated and approved every product it makes.
Likewise:
- FDA registration
- Laboratory testing
- A Certificate of Analysis
- ClinicalTrials.gov registration
- Manufacturing under a particular standard
do not automatically equal:
FDA approval for the treatment being advertised.
FDA specifically warns consumers that inclusion on ClinicalTrials.gov or registration with FDA does not, by itself, mean a regenerative medicine product is legally marketed or proven safe and effective. (U.S. Food and Drug Administration)
10. Question 8: What Are the Alternatives?
This may be the question most likely to disappear from online treatment marketing.
Suppose a patient has advanced knee osteoarthritis.
It is not enough to ask:
“Could regenerative therapy help?”
You also need to ask:
“Compared with what?”
Options may include:
- Physical therapy
- Exercise
- Weight management
- Medication
- Conventional injections
- Bracing
- Activity modification
- Surgery
- Doing nothing for now
For patients eligible for total knee replacement, randomized evidence has found greater pain and functional improvement after surgery than after nonsurgical treatment alone, but surgery also carried more serious adverse events. (PubMed)
Interestingly, the same research program found that many patients randomized initially to nonsurgical treatment were able to delay knee replacement for at least two years. (PubMed)
That is a much more useful conversation than:
“Surgery good.”
or:
“Surgery bad.”
Medicine is often about comparing tradeoffs.
11. How to Use PubMed When Researching Stem Cell Therapy
PubMed is maintained by the U.S. National Library of Medicine and is one of the most useful places to search biomedical literature.
You do not have to be a scientist to use it.
Instead of searching:
stem cells
try:
mesenchymal stromal cells knee osteoarthritis randomized placebo
or:
umbilical cord mesenchymal stromal cells rotator cuff human trial
The more specific the question, the more useful the results.
When you open a paper, look for:
Publication Date
Is it current?
Older research can still matter, but a 2011 article should not necessarily be treated as the final word in 2026.
Study Type
Randomized trial?
Observational study?
Case series?
Review?
Number of Patients
Ten patients and 500 patients provide different levels of certainty.
Control Group
Was the treatment compared with anything?
Product
What exact cells were used?
Results
What actually improved?
Conclusion
Did the researchers claim:
“effective”
or something much more cautious like:
“supports further investigation”?
Those are not the same thing.
12. Read the Methods, Not Just the Conclusion
You do not need to understand every statistical equation.
But look for basic details.
For example:
How many people started the trial?
How many finished?
Were patients randomized?
What was the comparator?
Were patients blinded?
Who funded the study?
What exact dose was used?
What type of cells?
How were they administered?
What was the primary endpoint?
Sometimes a study’s abstract sounds extremely exciting until you discover that:
- Only 12 patients participated
- There was no control group
- Results were self-reported
- The product is completely different from the one you’re considering
That does not make the study worthless.
It changes how much confidence you should place in it.
13. How to Use ClinicalTrials.gov
ClinicalTrials.gov is extremely useful for answering:
“What is currently being studied?”
You can search by:
- Condition
- Intervention
- Location
- Trial status
- Sponsor
- Trial phase
For example, active clinical trials continue to investigate MSC products for knee osteoarthritis. One study listed in 2026 is evaluating an allogeneic bone-marrow-derived MSC product against hyaluronic acid. (ClinicalTrials.gov)
That tells you:
research is actively happening.
It does not tell you:
the treatment has already been proven.
ClinicalTrials.gov explicitly states that the U.S. government does not review or approve the safety and science of every study listed in its database. Sponsors and investigators submit the information and remain responsible for the study’s science and accuracy. (ClinicalTrials.gov)
So:
Registered clinical trial ≠ FDA-approved treatment.
14. Recruiting Does Not Mean Proven
This distinction causes a lot of confusion.
If a trial says:
Recruiting
it means investigators are looking for participants.
It does not mean:
“The treatment works.”
The purpose of the study may literally be to find out whether it works.
Likewise:
Phase I often focuses heavily on safety and dose.
Phase II begins exploring effectiveness while continuing safety evaluation.
Phase III generally involves larger confirmatory testing.
Even a successful clinical trial does not automatically create an FDA-approved product.
15. How to Use AI When Researching Stem Cell Therapy
AI can be incredibly useful for medical research.
It can help you:
- Translate technical terminology
- Summarize an abstract
- Explain study design
- Compare papers
- Generate questions for your doctor
- Identify keywords to search
- Explain statistics in plain English
But AI should be treated as a research assistant, not the original scientific source.
A much better approach than asking:
“Do stem cells work for knee pain?”
is asking:
“Find randomized controlled human trials published since 2022 comparing mesenchymal stromal cells with placebo for knee osteoarthritis. Tell me the cell source, dose, number of participants, primary outcome, and whether the result was clinically significant. Give me the original paper for every claim.”
Then:
open the papers.
Do not stop at the AI summary.
16. Ask AI to Argue Against Its Own Answer
This is one of the simplest ways to improve a research conversation.
After AI gives you an encouraging answer, ask:
“What high-quality evidence contradicts this?”
Then ask:
“Are there randomized placebo-controlled studies that failed to show benefit?”
Then:
“Is the product in those studies actually the same product being offered to me?”
Then:
“What would a skeptical orthopedic surgeon say about this evidence?”
Then reverse it:
“What evidence would a regenerative medicine researcher point to?”
The goal is not to make AI decide who is right.
It is to expose yourself to the strongest arguments and evidence on both sides.
17. Ask AI for the Date
Medical information changes.
This is especially important in regenerative medicine.
For example, an older AI response may say:
“There are no FDA-approved mesenchymal stromal cell therapies.”
That statement became outdated on December 18, 2024, when FDA approved Ryoncil for a specific pediatric graft-versus-host disease indication. (U.S. Food and Drug Administration)
However, someone could then overcorrect and say:
“MSCs are FDA-approved now.”
That is also misleading because Ryoncil’s approval applies to a specific product, population, and indication. (U.S. Food and Drug Administration)
Dates matter.
Context matters.
18. Ask AI to Separate These Four Questions
When researching a regenerative treatment, have AI answer these separately:
1. Is there biological rationale?
Does laboratory or mechanistic research suggest the therapy could plausibly affect the condition?
2. Is there human evidence?
Has it actually been tested in people?
3. Is there evidence of clinical effectiveness?
Did controlled human trials demonstrate meaningful patient outcomes?
4. Is it FDA-approved for this indication?
Has the specific product completed the regulatory pathway for that particular use?
Those are four different questions.
Online discussions frequently collapse all four into:
“The science supports it.”
19. How to Evaluate a Clinic Website
A clinic’s website is useful for determining:
- What it offers
- Who works there
- How treatment is performed
- What philosophy the clinic has
- What claims it makes
It is not an independent source of evidence about its own treatment.
The Re/ Clinic maintains a scientific-resources page with outside research links intended to help patients explore the science behind treatments. (The Re/ Clinic)
When evaluating any clinic’s research page, including ours, ask:
Does the linked study use the same product?
A study titled “stem cells for knee OA” may involve bone-marrow MSCs while the clinic offers umbilical-cord-derived cells.
That matters.
Is the paper current?
Research evolves.
Is the study human?
Is it controlled?
Are limitations discussed?
A trustworthy education page should tell you what the evidence cannot establish too.
20. How to Evaluate Social Media Claims
Short-form video has an obvious limitation:
it is short.
A physician may have 30 seconds to explain a topic that requires a 20-page research paper.
That often leads to analogies and simplification.
Useful phrases to watch carefully include:
- “Repairs”
- “Regenerates”
- “Rebuilds”
- “Targets inflammation”
- “Goes where your body needs it”
- “Works for”
- “No rejection”
- “No side effects”
- “FDA compliant”
- “Clinically proven”
Those claims may have context behind them.
Your job is to ask:
How literally should I interpret that sentence?
That is exactly why many of the videos on The Re/ Clinic’s educational channels benefit from a longer article explaining the science, limitations, and current evidence.
21. Patient Testimonials: Useful, but for a Different Question
Testimonials answer questions like:
What was this person’s experience?
How was the clinic?
What was recovery like?
Did this particular patient feel better?
Those are legitimate questions.
But a testimonial cannot answer:
How likely is this treatment to work across patients like me?
Why?
Because you usually do not know:
- How many patients did not improve
- What else the patient was doing
- Whether symptoms would have changed anyway
- Whether expectations affected reporting
- Whether the diagnosis was identical to yours
A powerful testimonial can justify asking more questions.
It should not replace controlled evidence.
22. Before-and-After Imaging Needs Context Too
An MRI can look compelling.
But when evaluating before-and-after images, ask:
- Was imaging performed using the same technique?
- Same machine?
- Same positioning?
- Same sequences?
- Same radiologist?
- What interval passed?
- Was the patient treated with anything else?
- Was the change independently evaluated?
- Did the patient’s function improve too?
One image is not a clinical trial.
23. Red Flags When Researching Stem Cell Therapy
Be cautious when you see statements such as:
“This Works for Almost Everyone”
No medical treatment works for everyone.
“There Is Zero Risk”
No invasive medical procedure has zero risk.
“FDA Registered Means FDA Approved”
It does not.
“Thousands of Studies Prove Stem Cells Work”
Thousands of studies may involve completely different:
- Cell types
- Diseases
- animals
- laboratory models
- products
The number of search results is not an efficacy statistic.
“This Clinical Trial Proves Our Product Works”
Ask whether the trial actually tested their product.
“More Cells Means Better”
Dose-response must be established for the particular treatment.
“Stem Cells Will Regrow Your Cartilage”
A study showing pain improvement does not automatically prove clinically meaningful cartilage regeneration.
“You Don’t Need Surgery”
Sometimes surgery is the appropriate treatment.
A responsible regenerative consultation should be willing to say so.
24. A Good Clinic Should Be Willing to Discuss Negative Studies
Imagine asking:
“I found a placebo-controlled study where MSCs didn’t outperform saline. What do you think about it?”
A good response is not:
“That’s a bad study. Ours are better.”
At minimum, the provider should be able to discuss:
- What product the trial used
- How it differs from theirs
- Study strengths
- Study limitations
- Whether other trials agree
- What remains uncertain
For example, the negative 2025 ADIPOA2 trial involved autologous adipose-derived, culture-expanded MSCs, not the same type of donor-derived umbilical-cord product discussed at The Re/ Clinic. (PubMed)
That difference matters.
But it does not justify pretending the negative study does not exist.
25. Ask the Same Question About Positive Studies
The same scrutiny should apply to evidence that supports what you hope is true.
If you find a positive study, ask:
- Was it randomized?
- Was it blinded?
- How many patients?
- What was the control?
- Was the effect clinically meaningful?
- Who funded it?
- Did people drop out?
- Was cartilage actually regenerated?
- Has another group reproduced the result?
Confirmation bias works in both directions.
26. What Should You Bring to a Stem Cell Consultation?
Bring the questions.
Bring the MRI.
Bring the orthopedic recommendation.
Bring the article you found.
Bring the screenshot.
Bring the AI answer.
Bring the Reddit thread if it raised a real concern.
Then ask the provider to help you sort through it.
Questions worth bringing include:
“Does this paper use the same cells you’re offering me?”
“What evidence applies specifically to my diagnosis?”
“What evidence doesn’t support this treatment?”
“What would make you tell me I am not a candidate?”
“What is the FDA status of the product you’re using?”
“What outcome are we realistically trying to improve?”
“What can this treatment not do?”
“What would surgery accomplish that this treatment cannot?”
“If I delay surgery, what risk am I taking?”
“If this does not work, what is our next step?”
Those are excellent patient questions.
27. The Re/ Clinic’s Approach to an Informed Patient
Dr. Dame’s point in the video is one we strongly agree with:
Patients have access to more medical information than ever.
That should improve the conversation.
The purpose of a consultation should not be:
“Stop researching and trust us.”
It should be:
“Let’s look at what you found and determine how it actually applies to you.”
At The Re/ Clinic, regenerative treatment begins with:
- Diagnosis
- Medical history
- Imaging when relevant
- Previous treatment
- Patient goals
- Current evidence
- Product characteristics
- Realistic expectations
Our current osteoarthritis education specifically emphasizes education first and realistic expectations, rather than presenting regenerative treatment as guaranteed joint reconstruction. (The Re/ Clinic)
The most informed decision may be:
Proceed with treatment.
It may be:
Try conservative care first.
It may be:
See an orthopedic surgeon.
Or it may be:
This is not an appropriate regenerative case.
An informed consultation should leave room for all four answers.
Frequently Asked Questions
Can I trust AI for stem cell research?
AI can be useful for finding terminology, explaining research concepts, summarizing papers, and generating questions.
Do not rely on an AI summary alone to make a medical decision.
Open the original research and verify:
- Product
- Population
- Study design
- Outcome
- Publication date
- FDA status
What should I ask ChatGPT or another AI about stem cells?
Instead of:
“Do stem cells work?”
try:
“What randomized placebo-controlled human trials have studied this exact cell type for my diagnosis? Compare the results, sample sizes, primary endpoints, and limitations, and identify the original papers.”
Then read the papers.
Is PubMed reliable?
PubMed is an important database of biomedical literature maintained by the National Library of Medicine.
But a paper appearing in PubMed does not automatically make its conclusion correct.
You still need to evaluate study design, methodology, relevance, and whether results have been reproduced.
Does a study on ClinicalTrials.gov mean the treatment is approved?
No.
ClinicalTrials.gov explicitly states that the U.S. government does not review or approve the safety and science of every study in the database. (ClinicalTrials.gov)
Registration means the study is listed.
It does not establish treatment effectiveness or FDA approval.
Are any MSC therapies FDA-approved?
Yes.
Ryoncil became the first FDA-approved mesenchymal stromal cell therapy in December 2024.
It is approved specifically for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older. (U.S. Food and Drug Administration)
That approval does not extend to orthopedic or general regenerative uses.
Are stem cells FDA-approved for knee arthritis?
No MSC product is currently FDA-approved for knee osteoarthritis.
FDA continues to state that regenerative medicine products are not approved for orthopedic conditions including osteoarthritis and knee pain. (U.S. Food and Drug Administration)
Does one positive randomized trial prove stem cells work?
No.
Randomized controlled trials provide important evidence, but results need to be considered alongside:
- Other trials
- Study quality
- Cell source
- Product characteristics
- Dose
- Patient population
- Clinical significance
Different MSC trials have produced different results. (PubMed)
Does one negative trial prove stem cells do not work?
No.
A negative trial tells us something important about the particular treatment tested under those study conditions.
It does not necessarily answer every question about every cell product.
The correct response to conflicting evidence is to investigate why the results differ.
How do I know if a stem-cell study applies to The Re/ Clinic’s treatment?
Compare:
- Tissue source
- Autologous vs allogeneic
- Passage
- Processing
- Dose
- Route
- Diagnosis
- Disease severity
- Other treatments used
If these are different, the study may provide useful background without directly validating the exact clinic product.
Should I avoid surgery if I am considering regenerative treatment?
Not automatically.
For certain structural injuries and advanced joint disease, surgery may be an established and appropriate option.
Randomized evidence has shown greater improvement with total knee replacement than nonsurgical treatment in appropriately selected patients with moderate-to-severe knee osteoarthritis, although surgery also carries meaningful risks. (PubMed)
A regenerative consultation should not prevent someone from obtaining an orthopedic opinion.
Is a patient testimonial evidence?
It is evidence of that patient’s reported experience.
It is not strong evidence for determining the average treatment effect across patients.
Randomized controlled research is better suited to that question.
What if my doctor disagrees with something I found online?
Ask why.
A useful conversation might sound like:
“This paper says X. What am I misunderstanding?”
or:
“Is the product in this study different from the one you’re discussing?”
A provider should be able to explain the reasoning behind the disagreement.
Research More, Not Less
We do not think the answer to confusing medical information is to stop looking.
Research.
Ask AI.
Use PubMed.
Search ClinicalTrials.gov.
Read clinic websites.
Talk to orthopedic surgeons.
Read the studies supporting a treatment.
Then read the studies that challenge it.
The goal is not to become a stem-cell researcher overnight.
It is to know enough to ask:
What exactly are you giving me?
What evidence actually applies to me?
What are the limits of that evidence?
What are my other options?
and:
What result is realistic?
At The Re/ Clinic in Sandy, Utah, we welcome those conversations.
If you are researching regenerative medicine and have questions about studies, stem-cell products, imaging, surgical alternatives, or something you found online, bring it with you.
Schedule a regenerative medicine consultation with The Re/ Clinic and let us help you understand how the available research may or may not apply to your individual case.
Call: 385-240-1000
Location: 9035 S 700 E, Sandy, UT 84070
References
- U.S. Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-Refractory Acute Graft-Versus-Host Disease. December 18, 2024. Ryoncil became the first FDA-approved MSC therapy and is indicated specifically for pediatric steroid-refractory acute graft-versus-host disease. (U.S. Food and Drug Administration)
- U.S. Food and Drug Administration. RYONCIL. Current FDA product information describing remestemcel-L-rknd and its specific approved indication. (U.S. Food and Drug Administration)
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA guidance regarding unapproved regenerative products, orthopedic uses, misleading regulatory claims, and patient considerations. Note that older portions of this FDA page predate Ryoncil’s 2024 approval, so its statement about the overall number of approved stem-cell products is no longer current. Its orthopedic-use warnings remain relevant. (U.S. Food and Drug Administration)
- Pers YM, et al. Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial. Annals of the Rheumatic Diseases. 2025. The study did not find significant improvement in pain or function compared with saline placebo. (PubMed)
- Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study. Randomized trial of an allogeneic bone-marrow-derived MSC product reporting improvements in pain and function compared with placebo. (PubMed)
- Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial. Randomized human study reporting differences in WOMAC and KOOS outcomes at selected follow-up periods. (PubMed)
- ClinicalTrials.gov. About ClinicalTrials.gov and Disclaimer. Clarifies that the U.S. government does not review or approve the safety and science of every study listed and that sponsors or investigators provide study information. (ClinicalTrials.gov)
- American Academy of Orthopaedic Surgeons. Surgical Management of Osteoarthritis of the Knee Clinical Practice Guideline. Evidence-based guidance regarding surgical treatment for symptomatic knee osteoarthritis. (American Academy of Orthopaedic Surgeons)
- Skou ST, et al. A Randomized, Controlled Trial of Total Knee Replacement. New England Journal of Medicine. Total knee replacement plus nonsurgical treatment produced greater improvement than nonsurgical treatment alone among appropriately selected patients, while also producing more serious adverse events. (PubMed)
- Skou ST, et al. Total knee replacement and non-surgical treatment of knee osteoarthritis: 2-year outcome from two parallel randomized controlled trials. Osteoarthritis and Cartilage. Demonstrated that some patients eligible for knee replacement could delay surgery with structured nonsurgical care, although surgery produced greater average improvement. (PubMed)
- Utah Code § 58-1-512. Stem Cell Disclosure. Effective May 6, 2026. Requires a statutory notice for applicable non-FDA-approved stem-cell therapies, including applicable advertising. (Utah Legislature)
Utah Stem Cell Therapy Notice
THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW.
This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration.
You are encouraged to consult with your primary care provider before undergoing a stem cell therapy. (Utah Legislature)